Day 1 - Wednesday, 18 September 2019
Meeting category
Date(s)
18 Sep 2019
Location
Vilnius,
Lithuania
Organizer
Liverpool Course 2019
Program Overview
Opening session - 15:30
Anca Streinu-Cercel, MD, PhD
15:30 CEST
Registration and sandwich buffet
16:00 CEST
Opening of the Virtual Program: Welcome and Goals
Saye Khoo, PhD
University of Liverpool Liverpool, United Kingdom
Saulius Caplinskas, MD, PhD
ULAC, Lithuania
16:05 CEST
Introductory lecture + questions
16:35 CEST
Mini Lecture - HIV/HCV coinfection
17:05 CEST
Coffee break
17:25 CEST
Case 1: Multimorbidity + questions and discussion
17:55 CEST
Case 2: Woman with HBV/HCV coinfection + questions and discussion
National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Romania
18:25 CEST
Case 3: From Chemsex to intensive care, then back to Chemsex? + questions and discussion
18:55 CEST
Closing remarks
19:00 CEST
Dinner for All Participants
Main Program
Day 1 - Thursday, 19 September 2019
- 08:45
08:45 CEST
Opening of the Workshop
Session 1: Epidemiology of HIV and hepatitis in the CEE countries - 09:00
Anca Streinu-Cercel, MD, PhD
09:00 CEST
Epidemiology of viral hepatitis infection and treatment in CEE countries
09:30 CEST
Epidemiology of HIV infection and treatment in CEE countries
National Institute of Infectious Diseases "Prof. Dr. Matei Bals", Romania
10:00 CEST
Feasibility and acceptability of HCV self-testing
10:30 CEST
Coffee break and poster viewing
Session 2: Access to care - 11:00
11:00 CEST
EECA: Are we lagging behind?
11:10 CEST
Access to quality assured (WHO prequalified) generic medicines in the region
11:20 CEST
Access to key populations
11:30 CEST
Round Table Discussion
Session 3: HIV and Hepatitis co-infection - 11:45
11:45 CEST
Management of HIV/HCV co-infection in Young Women
12:00 CEST
Abstract-Driven Presentations
Door-to-door hepatitis C testing in three large cities of Georgia: A pilot study
Maia Butsashvili, Georgia
The prevalence of mutations of the Hepatitis C virus, associated with drug resistance to inhibitors of protein NS5A among patients of the republic of Belarus
Elena Gasich, Belarus
12:20 CEST
Discussion
12:30 CEST
Group Picture and Lunch
13:30 CEST
Industry-sponsored symposium
Session 4: PrEP - 14:30
14:30 CEST
PrEP and STI testing in CEE: What are the barriers, what works?
15:00 CEST
Abstract-driven presentations
Persistence on HIV pre-exposure prophylaxis medication: A challenge in pre-exposure prophylaxis (PrEP) program in Georgia
Ekaterine Karkashadze, Georgia
Virological efficacy of first-line regimens, resistance profile and factors influencing adherence to ART in clinical practice in Ukraine
Tetiana Kyrychenko, Ukraine
15:20 CEST
Discussion
15:30 CEST
Coffee Break and Poster Viewing
16:00 CEST
Industry-sponsored symposium
Session 5: Linkage to care and management of treatment failure in HIV - 17:00
17:00 CEST
Switching to second line HIV therapy
17:30 CEST
Integrated testing for HIV, hepatitis, and STIs
18:00 CEST
Discussion
18:15 CEST
End of Day 1: Welcome Reception and Poster Viewing
19:30 CEST
Workshop Dinner
Day 2 - Friday, 20 September 2019
Session 6: HIV and tuberculosis co-infection - 09:00
09:00
Management of TB and HIV infection
09:30 CEST
The challenging TB case: clinical, virological and pharmacological considerations
09:50 CEST
Discussion
10:00 CEST
Abstract-Driven Presentations
Epidemiology of HIV in the Baltic countries (Estonia, Latvia, Lithuania)
Saulius Čaplinskas, Lithuania
Uptake and outcomes of dolutegravir based antiretroviral therapy in Georgia
Nino Rukhadze, Georgia
The new tendencies in HIV and HCV epidemics in central region of Ukraine
Tetiana Koval, Ukraine
10:30 CEST
Coffee Break and Poster Viewing
Session 7: Abstract-driven presentations - 11:00
11:00 CEST
Management of Hepatitis C in primary healthcare in the country of Georgia
Akaki Abutidze
Georgia
11:10 CEST
HCV prevalence and associated factors among people who inject drugs (PWID): Baseline results of Georgian PWID cohort study
Ketevan Shermadini
Georgia
11:20 CEST
Diversity of HIV-1 subtypes in Russia 2009-2019
Konstantin Gromov
Russia
11:30 CEST
Outcomes for hepatitis B vaccination among HIV-infected adults in Georgia
Shorena Dvali
Georgia
11:40 CEST
Epidemiology of hepatitis B viral infection in the republic of Belarus
Viktar Mitsura
Belarus
11:50 CEST
Implementation of the State Program on elimination of viral hepatitis C in Ukraine: achievements and challenges
Kristyna Pronyuk
Ukraine
12:00 CEST
High level of integrase strand transfer inhibitors drug resistance mutations in INSTIs failed HIV-1 CRF06_cpx infected patients in Estonia
Merit Pauskar
-
12:00
Lunch
Session 8: Hot topics in HIV and hepatitis - 13:00
13:00 CEST
Treatment of Hepatitis B in Ukraine: What are the remaining challenges?
13:25 CEST
Vaccinations for HIV patients: which vaccinations when and how?
13:50 CEST
HIV/HCV Co-Infection: Influence on risk for cancer and cardiovascular events, and impact of successful HCV cure
14:15 CEST
The acute HCV Epidemic in MSM: What did we learn so far?
14:40 CEST
Closing remarks
Overview
Welcome
Designed and developed by renowned experts in the field of HIV care and pharmacology, The Liverpool Course aims to educate participants on key concepts in clinical pharmacology and drug-drug interactions, that remain a major consideration in the management of people living with HIV. It is organized in collaboration with the University of Liverpool and the leading experts who developed the Liverpool HIV drug interactions checker, a comprehensive drug-drug-interaction resource freely available to healthcare practitioners worldwide.
Program Chairs 2020
David Back
MD, PhD
Saye Khoo
MD PhD
Jonathan Schapiro
MD
General Information
Meeting Objectives
This meeting aims to:
- Reinforce and develop the understanding of key clinical pharmacology concepts among junior colleagues in the fields of infectious diseases and hepatology (clinicians, pharmacists, academics, industry colleagues etc.)
- Improve clinical pharmacology education and thereby the quality of patient care.
- Educate healthcare professionals on how to use the Liverpool Drug Interaction Resources in their clinical practice.
- Increase knowledge and confidence among healthcare professionals through practical examples of the Liverpool Drug Interactions Resources and discussion of case studies tailored to the local needs. doloremque laudantium
- Reinforce and develop the understanding of key clinical pharmacology concepts among junior colleagues in the fields of infectious diseases and hepatology (clinicians, pharmacists, academics, industry colleagues etc.)
- Improve clinical pharmacology education and thereby the quality of patient care.
- Educate healthcare professionals on how to use the Liverpool Drug Interaction Resources in their clinical practice.
- Increase knowledge and confidence among healthcare professionals through practical examples of the Liverpool Drug Interactions Resources and discussion of case studies tailored to the local needs. doloremque laudantium
Learning Objectives
After participating in this activity, participants will be able to:
- Describe in detail the terms pharmacodynamics and pharmacokinetics.
- Define what is meant by clinically significant DDI and discuss DDI mechanisms.
- Use the Liverpool DDI Resource with confidence in their daily practice.
- Identify the potential of DDIs of ARVs and DAAs and use this information to improve their decision making in daily practice.
- Describe in detail the terms pharmacodynamics and pharmacokinetics.
- Define what is meant by clinically significant DDI and discuss DDI mechanisms.
- Use the Liverpool DDI Resource with confidence in their daily practice.
- Identify the potential of DDIs of ARVs and DAAs and use this information to improve their decision making in daily practice.
Practical Information
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-meeting survey.
Language
The official language of the conference/meeting/workshop is English
Translation will not be provided.
Translation will not be provided.
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Downloads:
Support
Support
The Clinical Pharmacology and Antiviral Therapy: The Liverpool Course is supported by an independent educational grant from ViiV Healthcare.
ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
